首页> 美国卫生研究院文献>Journal of Clinical Laboratory Analysis >Comparison of Two Commercial ELISAs against an In‐House ELISA for Measuring Soluble CD26 in Human Serum
【2h】

Comparison of Two Commercial ELISAs against an In‐House ELISA for Measuring Soluble CD26 in Human Serum

机译:两种用于室内ELISA的商业ELISA的比较用于测量人血清中的可溶性CD26

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

CD26 is a T‐cell costimulatory molecule with dipeptidyl peptidase IV (DPPIV) activity in its extracellular region. The relevance of sCD26 levels and disease activity has been reported in rheumatic or infectious disease. For certain metabolic and endocrine conditions, DPPIV inhibitors were recently developed as a new class of antidiabetic drugs that act by inhibiting DPPIV, the enzyme that inactivates incretin hormone. Higher levels of sCD26 in diabetic patients have been shown to be associated with a poor clinical response to DPPIV inhibitors, with sCD26/DPPIV being an adipokine that may impair insulin sensitivity. With the increasing use of serum sCD26 and DPPIV enzyme activity as biomarkers with potential clinical implications, accurate measurements of serum sCD26 levels and DPPIV enzyme activity are needed.
机译:CD26是一种T细胞共刺激分子,在其细胞外区域具有二肽基肽酶IV(DPPIV)活性。在风湿性或传染性疾病中,已经报道了sCD26水平与疾病活性的相关性。对于某些代谢和内分泌疾病,最近开发了DPPIV抑制剂,它是一类新型的抗糖尿病药物,可通过抑制DPPIV(一种使肠降血糖素激素失活的酶)起作用。已显示糖尿病患者中较高水平的sCD26与对DPPIV抑制剂的不良临床反应有关,其中sCD26 / DPPIV是可能损害胰岛素敏感性的脂肪因子。随着血清sCD26和DPPIV酶活性作为具有潜在临床意义的生物标记物的使用越来越多,需要准确测量血清sCD26水平和DPPIV酶活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号